Key Drivers
- High Profitability
- Strong Cash Flow
- Low Leverage
AIAI Summary
REGN now looks less like a pipeline-driven biotech and more like a high-quality cash generator whose upside is increasingly capped by the melanoma-trial lawsuit, narrower growth dependence on Dupixent/EYLEA HD, and biosimilar pressure on EYLEA, so the stock is investable but only if you're comfortable paying for resilient execution rather than clean pipeline expansion.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High Profitability
- •Strong Cash Flow
- •Low Leverage
REGN continues to post strong profitability, solid cash generation, and low leverage, but softer cash balance growth and a full valuation suggest limited near-term upside.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Breakout hold
- •Overbought rally
REGN has been in a strong last month uptrend, holding above prior breakout levels and testing $806-$808 resistance, but the fast move leaves it stretched and vulnerable to a pullback if $784-$785 breaks.
Sharp climb from the mid-$670s to $803.48 in a short span suggests short-term volatility risk
Sentiment & News
Key News Insights:
- •Dupixent Momentum
- •Trial Failure
- •Deadline Risk
Regeneron's strong Eylea HD/Dupixent-driven growth and oncology progress are being offset by persistent shareholder litigation over a failed melanoma trial and a looming lead-plaintiff deadline.
The stock may stay supported by core commercial strength, but ongoing legal headlines could cap upside and keep volatility elevated
Similar Companies in Healthcare
Other companies in the same sector with AI ratings